Leverkusen is one of the word’s most versatile locations for the chemical industry. More than 5,000 chemicals are manufactured here and, if necessary, disposed of safely. Contaminated hazardous waste is handled expertly at our Bürrig waste management plant, which is far from being just a regional facility.
The 470-hectare Leverkusen site offers excellent opportunities for all kinds of companies – from the chemical and pharmaceutical industries to the high-tech sector. More than 5,000 chemicals and pharmaceuticals are manufactured at CHEMPARK in Leverkusen, mainly nitration and chlorination products, aromatics, fine chemicals and silicon chemicals. Around 30,000 people work here, ensuring that the CHEMPARK skills center keeps on developing. Know-how, efficiency and responsibility are key to the success of this Chemical site.
Environmental protection and safety are considered just as important as cost-effectiveness and product quality. The Leverkusen site’s safety control center is one of the most modern safety facilities in the entire chemical industry. The site also boasts cutting-edge waste management technology. Thanks to its ultra-modern rotary kiln furnace, the Bürrig waste management plant can dispose of contaminated hazardous waste both safely and efficiently – a service that is unrivaled anywhere in Europe.
The Leverkusen site is also located in a part of Germany where both the standard of living and the quality of life are high – in urban and rural areas alike. It is located close to the major Rhineland cities of Cologne and Düsseldorf, which has the largest Japanese community in Germany. Both cities are important media centers and exhibition venues. With international schools and a superb choice of cultural attractions on its doorstep, CHEMPARK has everything a company and its workforce could wish for.
2017-01-01€ 5 mln
2017-01-01€ 40 mln Investment details
LANXESS enters battery chemistry business: electrolyte production for lithium-ion batteries in Leverkusen, Germany
Electrolyte production for Guangzhou Tinci Materials Technology Co. to start in Leverkusen in 2022. Use of a high-tech plant of LANXESS subsidiary Saltigo
WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany
First drug product facility in Europe to complement WuXi Biologics’ existing commercial manufacturing capacities. WuXi Biologics will be the back-up manufacturer for Kovaltry™ of Bayer
LANXESS successfully completes plant expansion for Macrolex dyes
Capacity increased by around 25 percent. Investment of more than five million euros contributes to site security
LANXESS strengthens global production network for flame retardants
Investments of around EUR 200 million until 2021 in the U.S. (Charleston, El Dorado, Greensboro), Germany (Leverkusen, Krefeld-Uerdingen), France (Épierre) and the United Kingdom (Manchester)